 Home > Medical News > Latest Medical News > The first three-generation BCR-ABL TKI in China!

The first three-generation BCR-ABL TKI in China!

 Last Update: 2021-12-04
 Source: Internet
 Author: User

Tags

brca abl

benefits stem cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 25, the National Medical Products Administration (NMPA) approved the marketing of Oribatinib (trade name: Nerlik) for the treatment of chronic or accelerated adult chronic patients with TKI resistance and T315I mutation.

CML, also known as chronic myeloid leukemia, is a malignant tumor formed by the clonal proliferation of bone marrow hematopoietic stem cells, which is a type of leukemia

The first indication developed by oribatinib is Bcr-Abl T315I mutant CML.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.